These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 14692710)

  • 21. Liposomal co-delivered oleanolic acid attenuates doxorubicin-induced multi-organ toxicity in hepatocellular carcinoma.
    Sarfraz M; Afzal A; Raza SM; Bashir S; Madni A; Khan MW; Ma X; Xiang G
    Oncotarget; 2017 Jul; 8(29):47136-47153. PubMed ID: 28525367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
    Bakker M; Droz JP; Hanauske AR; Verweij J; van Oosterom AT; Groen HJ; Pacciarini MA; Domenigoni L; van Weissenbruch F; Pianezzola E; de Vries EG
    Br J Cancer; 1998; 77(1):139-46. PubMed ID: 9459159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro study of the binding of doxorubicin to heart.
    Alvarez-Cedrón L; López FG; Lanao JM
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):132-6. PubMed ID: 9725470
    [No Abstract]   [Full Text] [Related]  

  • 24. Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.
    Völler S; Boos J; Krischke M; Würthwein G; Kontny NE; Boddy AV; Hempel G
    Clin Pharmacokinet; 2015 Nov; 54(11):1139-49. PubMed ID: 25925711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
    Otterson GA; Villalona-Calero MA; Sharma S; Kris MG; Imondi A; Gerber M; White DA; Ratain MJ; Schiller JH; Sandler A; Kraut M; Mani S; Murren JR
    Clin Cancer Res; 2007 Feb; 13(4):1246-52. PubMed ID: 17317836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.
    Krischke M; Hempel G; Völler S; André N; D'Incalci M; Bisogno G; Köpcke W; Borowski M; Herold R; Boddy AV; Boos J
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1175-1184. PubMed ID: 27770238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems.
    Dubbelboer IR; Lilienberg E; Ahnfelt E; Sjögren E; Axén N; Lennernäs H
    Ther Deliv; 2014 Apr; 5(4):447-66. PubMed ID: 24856170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.
    Wittenburg LA; Thamm DH; Gustafson DL
    Vet Comp Oncol; 2014 Jun; 12(2):114-9. PubMed ID: 22747489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
    Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
    Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response.
    Elis A; Lishner M; Walker S; Atias D; Korenberg A; Koren G
    Ther Drug Monit; 2010 Feb; 32(1):50-2. PubMed ID: 19927044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
    Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice.
    Freeland MM; Angulo J; Davis AL; Flook AM; Garcia BL; King NA; Mangibin SK; Paul KM; Prosser ME; Sata N; Bentley JL; Olson LE
    Anticancer Drugs; 2012 Jul; 23(6):584-9. PubMed ID: 22343424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
    Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
    Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
    Synold TW; Doroshow JH
    J Infus Chemother; 1996; 6(2):69-73. PubMed ID: 8809652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin.
    Martin RC; Robbins K; Fagés JF; Romero FD; Rustein L; Tomalty D; Monaco R
    Breast Cancer Res Treat; 2012 Apr; 132(2):753-63. PubMed ID: 22200868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
    Amantea MA; Forrest A; Northfelt DW; Mamelok R
    Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats.
    Vaidyanathan S; Boroujerdi M
    Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.
    Vaccaro M; Santarpia M; Calapai G; Mannucci C; Borgia F; Altavilla G; Cannavò SP
    Br J Dermatol; 2017 Feb; 176(2):507-509. PubMed ID: 27291307
    [No Abstract]   [Full Text] [Related]  

  • 39. Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.
    Quintieri L; Rosato A; Amboldi N; Vizler C; Ballinari D; Zanovello P; Collavo D
    Br J Cancer; 1999 Mar; 79(7-8):1067-73. PubMed ID: 10098738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
    Rudek MA; Sparreboom A; Garrett-Mayer ES; Armstrong DK; Wolff AC; Verweij J; Baker SD
    Eur J Cancer; 2004 May; 40(8):1170-8. PubMed ID: 15110880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.